Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Часто задаваемые вопросы
В каком секторе работает Beta Bionics, Inc. Common Stock (BBNX)?
Beta Bionics, Inc. Common Stock относится к сектору Здравоохранение.
Какова текущая цена акций Beta Bionics, Inc. Common Stock (BBNX)?
По последним данным, цена акций Beta Bionics, Inc. Common Stock составляет 15,90 $, предыдущее закрытие — 14,11 $. За последнюю торговую сессию акции Beta Bionics, Inc. Common Stock выросли на 1,79 $, что соответствует росту на 12,69%.
Выплачивает ли Beta Bionics, Inc. Common Stock (BBNX) дивиденды?
Нет, Beta Bionics, Inc. Common Stock не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Beta Bionics, Inc. Common Stock (BBNX)?
У компании Beta Bionics, Inc. Common Stock бета 0.644, что указывает на более низкую волатильность по сравнению с рынком в целом.
